📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
33 announcements match the current filters (relevance ≥ 5).
Cohance Lifesciences Appoints Umang Vohra as Chairman & CEO; Approves 6.25% ESOP Plan
Cohance Lifesciences has announced a major leadership transition, appointing industry veteran Umang Vohra as Chairman and Group CEO for a five-year term starting May 2026. Outgoing Executive Chairman Vivek Sharma will resign effective April 30, 2026, but will continue as a Special Advisor for nine months to facilitate a smooth transition. Additionally, the board approved the ESOP 2026 scheme, which involves 25.9 million options representing 6.25% of the company's fully diluted equity. Total dilution from all employee stock plans is projected to be capped at 7.75% over the next 7.5 years.
Key Highlights
Appointment of Umang Vohra as Chairman (May 1) and Group CEO (May 20) for a 5-year tenure until 2031
Approval of ESOP 2026 covering 25,918,613 options, equivalent to 6.25% of fully diluted equity capital
Total equity dilution from ESOP 2023 and 2026 capped at 7.75% over 7.5 years, averaging ~1% per annum
Minimum exercise price for ESOPs set at INR 325 per share, representing a 2.5% discount to the 21-day average price
Outgoing Chairman Vivek Sharma to serve as Special Advisor for 9 months to ensure business continuity
👀 What to Watch
Investors should view the appointment of Umang Vohra, a seasoned pharma leader, as a positive catalyst for long-term growth. Monitor the execution of the transition and the impact of the new incentive structure on management performance.
Cohance Lifesciences Revises FY26 Revenue Outlook to Double-Digit Decline; Q3 CDMO Down 27%
Cohance Lifesciences reported a challenging Q3 FY26, with Pharma CDMO revenue declining 27% YoY due to inventory destocking and patent expiries in key molecules. Consequently, the company has revised its FY26 revenue guidance to an early-to-mid double-digit decline, citing a transition year impacted by customer-led timing delays. Despite these headwinds, the company maintains a robust pipeline with 9 Phase 3 programs and expects a recovery in FY27 driven by new product launches. Management is also investing $10 million in US-based capacity to strengthen its Antibody-Drug Conjugate (ADC) platform.
Key Highlights
Revised FY26 revenue outlook downward to an early-to-mid double-digit decline.
Pharma CDMO revenue fell 27% YoY in Q3 FY26, though adjusted growth was 7% excluding destocking.
Currently supporting 9 Phase 3 molecules, with 4 expected to move into commercial supply in FY27.
Investing $10 million in a cGMP US-based expansion for ADC supply capability by end of FY27.
Nacharam facility remediation is ongoing following a USFDA warning letter, with production resumed for non-US markets.
👀 What to Watch
Investors should remain cautious as the significant guidance cut suggests near-term earnings pressure and execution risks. Monitor the successful commercialization of the four Phase 3 assets in FY27 and the resolution of the USFDA warning letter as key recovery indicators.
Cohance Lifesciences Q3 Revenue Drops 19.5%; FY26 Guidance Revised to Double-Digit Decline
Cohance Lifesciences reported a weak Q3 FY26 with revenue declining 19.5% YoY to ₹5,446 mn and Adjusted PAT plunging 87.3% to ₹211 mn. The company has revised its FY26 revenue guidance from a flat outlook to an early-to-mid double-digit decline, citing inventory normalization and regulatory disruptions. Despite the downturn, gross margins improved to 72.8% for 9M FY26, and the company maintains a healthy cash position of ₹4.32 Bn. Management views FY26 as a transition year and expects a return to growth in FY27.
Key Highlights
9M FY26 Adjusted EBITDA fell 43.4% YoY to ₹3,477 mn, with margins compressing from 34.8% to 21.1%.
Pharma CDMO revenue for Q3 fell to ₹2,105 mn, impacted by customer-led inventory normalization and payload timing.
Regulatory issues at the Nacharam plant led to a Warning Letter and approximately ₹55 crore in shipment deferrals.
Company generated ₹1.75 Bn in free cash flow during 9M FY26 despite significant operational headwinds.
Revised FY26 outlook projects a double-digit revenue decline, shifting the recovery timeline to FY27.
👀 What to Watch
Investors should exercise caution as the company navigates a transition phase and regulatory hurdles at its Nacharam site. Monitor the execution of the commercial pipeline and the anticipated recovery in the CDMO segment in FY27.
Cohance Lifesciences Q3 FY26 Consolidated Net Profit Drops 81% YoY to ₹29.02 Crore
Cohance Lifesciences (formerly Suven Pharmaceuticals) reported a weak set of numbers for Q3 FY26, with consolidated revenue falling 19.5% YoY to ₹544.55 crore. Net profit saw a massive decline of 81%, dropping to ₹29.02 crore from a restated ₹153.48 crore in the previous year's corresponding quarter. The results are heavily impacted by the restatement of accounts following the merger of Casper Pharma and the erstwhile Cohance Lifesciences. Additionally, an exceptional cost of ₹4.86 crore was recorded due to new labor code implementations.
Key Highlights
Consolidated Revenue from operations fell to ₹544.55 crore in Q3 FY26 from ₹676.23 crore (restated) in Q3 FY25.
Consolidated Net Profit plummeted 81% YoY to ₹29.02 crore compared to ₹153.48 crore in the year-ago period.
Consolidated EPS for the quarter stood at ₹0.96, down significantly from ₹4.02 in Q3 FY25.
Total expenses remained high at ₹505.25 crore despite the drop in revenue, impacting operating margins.
Exceptional items for the quarter included a ₹4.86 crore charge for the implementation of new labor codes.
👀 What to Watch
Investors should be cautious as the post-merger entity is showing significant margin pressure and a sharp decline in profitability. It is advisable to wait for management commentary on merger synergies and recovery timelines in the CDMO segment before making new entries.
Cohance Lifesciences Receives USFDA Warning Letter for Hyderabad Unit; Financial Impact <2% Revenue
Cohance Lifesciences (formerly Suven Pharmaceuticals) has received a formal Warning Letter from the USFDA for its Finished Dosage Formulations (FDF Unit-I) facility in Nacharam, Hyderabad. This follows an August 2025 inspection that resulted in six observations and an 'Official Action Indicated' (OAI) classification. The company noted that the facility's contribution to consolidated FY25 revenue is less than 2%, with an EBITDA impact of less than 1%. Management is currently preparing a comprehensive response and implementing corrective actions to address the regulator's concerns.
Key Highlights
USFDA issued a Warning Letter for the FDF Unit-I facility following an inspection in August 2025.
The facility was previously classified as Official Action Indicated (OAI) based on six observations.
Financial impact is limited, with the unit contributing less than 2% of consolidated FY25 revenues.
EBITDA contribution from the affected facility is less than 1% of the company's total.
Company is proactively engaging with the USFDA to submit a response within stipulated timelines.
👀 What to Watch
While the immediate financial impact is minimal, investors should monitor the resolution timeline as a Warning Letter can stall new product approvals from this site. Watch for management updates regarding the successful implementation of corrective actions and the lifting of the OAI status.
Cohance Lifesciences Receives USFDA Warning Letter for Nacharam Facility
Cohance Lifesciences has received a formal Warning Letter from the USFDA regarding its Finished Dosage Formulations facility (FDF Unit-I) in Nacharam, Hyderabad. This follows an inspection conducted in August 2025 and a previous classification of the site as Official Action Indicated (OAI). Management has clarified that the financial impact is limited, as US revenues from this facility contributed less than 2% of consolidated revenues in FY2025. The company is currently working with the regulator to address compliance concerns and resolve the issues at the earliest.
Key Highlights
USFDA issued a Warning Letter for the Nacharam formulation facility following an August 2025 inspection.
The facility's US-linked revenue accounted for less than 2% of consolidated revenues in FY2025.
Related EBITDA contribution from the facility was less than 1% of the total in FY2025.
The site was previously classified as Official Action Indicated (OAI) prior to this Warning Letter.
Company is engaging with the USFDA to remediate the observations and ensure regulatory compliance.
👀 What to Watch
Investors should note that while the immediate financial impact is minimal, a Warning Letter typically halts new product approvals from the affected site. Monitor the company's progress in resolving the USFDA observations to ensure no further escalation or spillover to other facilities.
Cohance Lifesciences Appoints Sunil Kumar Singh as Chief Quality Officer
Cohance Lifesciences has appointed Mr. Sunil Kumar Singh as Chief Quality Officer and Senior Management Personnel, effective January 19, 2026. Mr. Singh brings over 35 years of extensive experience in pharmaceutical quality management across APIs, formulations, and CDMO sectors. He previously served as the Global Head of Quality for the PSAI Business at Dr. Reddy’s Laboratories and held senior roles at Mylan and Cipla. This strategic hire is intended to strengthen the company's regulatory compliance and quality governance frameworks.
Key Highlights
Mr. Sunil Kumar Singh appointed as Chief Quality Officer and Senior Management Personnel effective January 19, 2026.
Brings over 35 years of leadership experience in pharmaceutical quality, including APIs and CDMO ecosystems.
Former Global Head of Quality for PSAI Business and Global Head of Internal Audit at Dr. Reddy’s Laboratories.
Extensive career history with leading pharmaceutical firms including Mylan, Zydus, Glenmark, and Cipla.
Focus will be on science-driven quality transformation, digitalization, and proactive risk governance.
👀 What to Watch
Investors should view this as a positive development for the company's operational stability and regulatory standing. No immediate action is required, but the appointment of a high-caliber veteran from Dr. Reddy's strengthens the management team.
Cohance Lifesciences Seeks Approval for Himanshu Agarwal as WTD and CFO for 5-Year Term
Cohance Lifesciences Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Himanshu Agarwal as a Whole-time Director and Chief Financial Officer. The proposed appointment is for a five-year tenure, effective from October 29, 2025, to October 28, 2030. Shareholders can participate in the remote e-voting process which commences on December 24, 2025, and concludes on January 22, 2026. This move aims to formalize his position after his initial appointment as an Additional Director by the Board.
Key Highlights
Appointment of Mr. Himanshu Agarwal as Whole-time Director and CFO for a period of 5 years.
The term of appointment is set from October 29, 2025, through October 28, 2030.
Remote e-voting period is scheduled from December 24, 2025 (9:00 AM) to January 22, 2026 (5:00 PM).
The cut-off date for determining shareholder eligibility for voting was December 19, 2025.
Final voting results are expected to be declared on or before January 23, 2026.
👀 What to Watch
Investors should take note of the leadership continuity in the finance function and may participate in the e-voting process as per the provided schedule. This is a routine regulatory requirement for confirming executive appointments.
Cohance Lifesciences Resubmits Financial Results for Q2 2026
Cohance Lifesciences Limited has resubmitted its Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025, in machine-readable form, as per NSE requirements. The original results were submitted on November 12, 2025, and there are no changes in the financials. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹497.79 crore, and net profit for the period was ₹94.19 crore. Consolidated revenue from operations for the quarter ended September 30, 2025, was ₹555.57 crore, with a net profit of ₹66.39 crore.
Key Highlights
Standalone revenue from operations for Q2 2026: ₹497.79 crore
Standalone net profit for Q2 2026: ₹94.19 crore
Consolidated revenue from operations for Q2 2026: ₹555.57 crore
Consolidated net profit for Q2 2026: ₹66.39 crore
Total standalone income for half year ended September 30, 2025: ₹1020.77 crore
👀 What to Watch
Review the detailed financial results for Cohance Lifesciences to assess the company's performance and consider how it aligns with your investment strategy. Monitor future announcements for any significant changes in financial performance.
COHANCE Appoints Senior Management Personnel Effective Dec 5, 2025
Cohance Lifesciences Limited announced the appointment of three Senior Management Personnel effective December 5, 2025. Mr. Gunjan Singh is appointed as Business Head – API plus, bringing over two decades of experience. Mr. Amrit Singh is appointed as Head – Specialty Chemicals, with over 20 years of leadership experience. Mr. Ravinatha Shetty is appointed as Platform Chief Operating Officer, bringing nearly 35 years of experience. These appointments aim to strengthen operational excellence and accelerate organizational growth.
Key Highlights
Mr. Gunjan Singh appointed as Business Head – API plus effective December 5, 2025.
Mr. Amrit Singh appointed as Head – Specialty Chemicals effective December 5, 2025.
Mr. Ravinatha Shetty appointed as Platform Chief Operating Officer effective December 5, 2025.
Mr. Gunjan Singh has over two decades of experience.
Mr. Amrit Singh has over 20 years of leadership experience.
👀 What to Watch
Investors should monitor the impact of these leadership changes on the company's strategic growth and operational efficiency. Review the company's future performance and strategic direction under the new management.
Cohance Lifesciences Receives Credit Rating of IND AA/Stable/IND A1+
India Ratings & Research has assigned a credit rating of IND AA/Stable/IND A1+ to Cohance Lifesciences Limited's bank loan facilities. The rating applies to bank loan facilities totaling ₹6,850 million. This rating indicates a stable outlook for the company's ability to meet its financial obligations. Investors should note this positive credit rating as an indicator of the company's financial health.
Key Highlights
Bank loan facilities rated at IND AA/Stable/IND A1+
Total size of bank loan facilities rated is ₹6,850 million
Citibank N.A. term loan rated IND AA/Stable with an outstanding amount of ₹343.00 million
Axis Bank Limited term loan rated IND AA/Stable with an outstanding amount of ₹833.00 million
State Bank of India fund-based working capital limits rated IND AA/Stable/IND A1+ with an outstanding amount of ₹1300.00 million
👀 What to Watch
Investors can view this credit rating as a positive signal regarding Cohance Lifesciences' financial stability. Monitor future credit rating updates for any changes that may affect the company's outlook.
Cohance Lifesciences grants 80,15,626 stock options under ESOP 2023
Cohance Lifesciences Limited has announced the grant of 80,15,626 stock options to eligible employees under its Employee Stock Option Plan 2023. These options are exercisable into 80,15,626 equity shares of Re. 1 each. The options will vest between 1 to 10 years from the grant date, and can be exercised within 3 years from the vesting date. The ESOP 2023 scheme is formulated in accordance with SEBI regulations.
Key Highlights
Granted 80,15,626 stock options to employees.
Each option entitles the holder to 1 equity share of Re. 1.
Vesting period ranges from 1 to 10 years.
Exercise period is up to 3 years from vesting.
👀 What to Watch
Investors should monitor the potential dilution effect on equity from the exercise of these options. Review the company's disclosures on its website for full details of the ESOP 2023.
Cohance Lifesciences to Invest Up to USD 10 Million in US Subsidiary NJ Bio Inc
Cohance Lifesciences (formerly Suven Pharmaceuticals) has approved a fund infusion of up to USD 10 million into its US-based subsidiary, NJ Bio Inc. The investment will be structured as Compulsorily Convertible Preferred Stock. The primary objective of this capital injection is to support NJ Bio's growth initiatives, specifically focusing on capital expenditure (capex). This move signals the company's commitment to scaling its international operations and enhancing its subsidiary's service capabilities.
Key Highlights
Board approved investment of up to USD 10 million in NJ Bio Inc, USA.
Investment to be made via Compulsorily Convertible Preferred Stock.
Funds are earmarked for growth initiatives and capital expenditure (capex).
NJ Bio Inc is a direct subsidiary of Cohance Lifesciences Limited.
Detailed disclosures will follow after the subsidiary's board approval.
👀 What to Watch
Investors should monitor the progress of NJ Bio's capex projects as they are likely to drive future revenue growth for the consolidated entity.
